Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$219,583 Mln
Revenue (TTM)
$54,982 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
10.1 %
P/E Ratio
28.5
P/B Ratio
5.3
Industry P/E
--
EV/EBITDA
15.3
Div. Yield
2.2 %
Debt to Equity
0.7
Book Value
$26.5
EPS
$1.8
Face value
--
Shares outstanding
3,100,430,080
CFO
$54,607.00 Mln
EBITDA
$79,906.00 Mln
Net Profit
$26,599.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AstraZeneca - ADR
| 6.8 | 0.4 | -8.3 | -10.8 | 4.6 | 5.7 | 7.7 |
|
BSE Sensex*
| 4.5 | 1.0 | 6.3 | 5.9 | 16.4 | 18.6 | 11.4 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
AstraZeneca - ADR
| -2.7 | -0.7 | 16.4 | 16.5 | 0.3 | 31.3 | 9.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
70.0 | 219,583.2 | 54,982.0 | 7,772.0 | 20.0 | 19 | 28.5 | 5.3 |
| 91.5 | 13,228.2 | 1,037.0 | 896.0 | 110.7 | 9.2 | 14.6 | 1.3 | |
| 92.3 | 13,206.4 | 1,037.0 | 896.0 | 110.7 | 9.2 | 14.7 | 1.3 | |
| 203.1 | 4,590.0 | 1,062.5 | 65.9 | 6.5 | -- | 1005.8 | 1.6 | |
| 171.8 | 5,179.3 | 5,356.0 | 655.0 | 24.2 | 31.2 | 8.8 | 2.3 | |
| 23.0 | 8,550.8 | 28,720.0 | -5,320.0 | -16.7 | -32.3 | -- | 0.9 | |
| 12.4 | 8,758.6 | 28,720.0 | -5,320.0 | -16.7 | -32.3 | -- | 0.5 | |
| 81.0 | 11,942.9 | 4,252.1 | -106.0 | -1.1 | -4.3 | -- | 4.7 | |
| 21.8 | 7,349.9 | 8,605.0 | -1,649.0 | -16.9 | -10.8 | -- | 0.7 | |
| 16.6 | 2,674.5 | 3,067.8 | 467.0 | 24.8 | 15.8 | 5.9 | 0.9 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,... Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Read more
CEO & Executive Director
Mr. Pascal Soriot D.V.M., M.B.A.
CEO & Executive Director
Mr. Pascal Soriot D.V.M., M.B.A.
Headquarters
Cambridge
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of AstraZeneca PLC - ADR stood at $ 135,382 Mln as on 31-Mar-25
The share price of AstraZeneca PLC - ADR is $69.95 (NASDAQ) as of 20-Jun-2025 16:12 EDT. AstraZeneca PLC - ADR has given a return of 4.62% in the last 3 years.
AstraZeneca PLC - ADR has a market capitalisation of $ 219,583 Mln as on 20-Jun-2025. As per Value Research classification, it is a company.
The P/B ratio of AstraZeneca PLC - ADR is 5.28 times as on 20-Jun-2025, a 795% premium to its peers’ median range of 0.59 times.
The P/E ratio of AstraZeneca PLC - ADR is 28.53 times as on 20-Jun-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the AstraZeneca PLC - ADR and enter the required number of quantities and click on buy to purchase the shares of AstraZeneca PLC - ADR.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
The CEO & director of Mr. Pascal Soriot D.V.M., M.B.A.. is AstraZeneca PLC - ADR, and CFO & Sr. VP is Mr. Pascal Soriot D.V.M., M.B.A..
There is no promoter pledging in AstraZeneca PLC - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
851
|
|
|
1,274
|
|
|
1,274
|
|
|
1,194
|
|
|
851
|
|
|
726
|
|
|
502
|
|
|
459
|
|
|
265
|
| AstraZeneca PLC - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
18.99
|
|
Operating margin(%)
|
19.97
|
|
Net Margin(%)
|
14.14
|
|
Dividend yield(%)
|
2.19
|
No, TTM profit after tax of AstraZeneca PLC - ADR was $0 Mln.
$-0.81
(
